Published in J Hepatol on April 04, 2017
Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. Oncotarget (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene (2010) 4.00
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol (2006) 3.31
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology (2009) 3.03
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet (2013) 2.83
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
S100A4 and metastasis: a small actor playing many roles. Am J Pathol (2009) 2.80
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol (2011) 2.59
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science (2014) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Inside the human cancer tyrosine phosphatome. Nat Rev Cancer (2011) 2.38
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature (2016) 2.35
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol (2015) 1.92
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol (2014) 1.76
Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 1.71
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology (2014) 1.64
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist (2014) 1.61
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet (2014) 1.60
Genomic spectra of biliary tract cancer. Nat Genet (2015) 1.58
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol (2010) 1.49
An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. Gastroenterology (2015) 1.43
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer (2016) 1.42
A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2013) 1.42
Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology (2002) 1.38
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology (2014) 1.38
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One (2014) 1.38
Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell (2016) 1.32
Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol (1998) 1.29
Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis (2014) 1.28
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology (2011) 1.23
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun (2015) 1.22
MET signaling pathway: a rational target for cancer therapy. J Clin Oncol (2011) 1.17
The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem (2013) 1.12
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep (2016) 1.11
A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol (2014) 1.10
Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer (2013) 1.09
Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res (2010) 1.08
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 1.07
Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology (2013) 1.07
Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer (2010) 1.05
Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol (2014) 1.02
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res (2014) 1.00
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A (2014) 0.99
Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol (2006) 0.98
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol (2013) 0.98
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol (2012) 0.96
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology (2011) 0.96
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. J Med Chem (2014) 0.96
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med (2016) 0.95
Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol (2009) 0.94
Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int (2009) 0.92
Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol (2013) 0.91
Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease. Lab Invest (2011) 0.91
Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surg Nutr (2013) 0.89
Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem (2014) 0.88
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov (2016) 0.85
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol (2014) 0.85
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist (2015) 0.84
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol (2014) 0.84
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs (2014) 0.84
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res (2015) 0.83
Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 0.81
Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. Int Surg (2013) 0.80
PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer (2010) 0.80
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs (2014) 0.80
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One (2016) 0.80
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology (2013) 0.79
Cholangiocarcinoma. Lancet (2014) 4.52
Targeting cholangiocarcinoma. Biochim Biophys Acta (2017) 0.75